SCHEMBL6317072

SCHEMBL6317072

NC(=O)c1c(-c2cccnc2)noc1NC(=O)COc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.55
RAB9A P51151 3/20 0.47
GALR3 O60755 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.45
NAMPT P43490 1/20 0.45
MAPT P10636 3/20 0.45
HAVCR2 Q8TDQ0 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
THRB P10828 1/20 0.43
NPC1 O15118 2/20 0.42
TP53 P04637 1/20 0.42
MAPK10 P53779 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TNF P01375 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322876 0.88 LMNA (0.55) NOTUMRAB9AGALR3LMNAGAA
SCHEMBL6317636 0.86 ALDH1A1 (0.43) NOTUMRAB9APOLBGAAMAPT
SCHEMBL6316529 0.80 ALDH1A1 (0.43) LMNAPOLBGAAMAPTKDM4E
SCHEMBL6319422 0.79 NPC1 (0.55) NOTUMRAB9ATDP1LMNAPOLB
SCHEMBL6317074 0.79 ALDH1A1 (0.48) RAB9ALMNAPOLBGAAKDM4E
SCHEMBL6321895 0.79 MAPT (0.54) RAB9ATDP1LMNAPOLBGAA
SCHEMBL6316996 0.75 KMT2A (0.44) LMNAPOLBGAAKDM4EALDH1A1
SCHEMBL6316499 0.75 ADORA2B (0.52) GAAKDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL6316651 0.75 ALDH1A1 (0.57) RAB9ATDP1LMNAGAAMAPT
SCHEMBL6315883 0.74 SMN1; SMN2 (0.52) RAB9ATDP1GAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 NOTUM 4254/4885RAB9A 1754/4885GALR3 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.